Despite Recent Speed Bumps, Biogen's Stock Will Soon Grow Again

Biogen (NASDAQ: BIIB) hasn't been the world's most reliable biotech stock over the past five years. Major setbacks in its Alzheimer's disease drug-development pipeline have crimped growth, and the withdrawal from the market of its multiple sclerosis drug Zinbryta caused potential investors to be skeptical.

Indeed, investing in Biogen in 2016 and selling today would have meant a loss of 16.6%. The company offers no dividends, nor does it plan to. Unlike other biotech companies of a similar size, Biogen doesn't develop drugs in lucrative disease areas -- think oncology, hypertension, or arthritis. As a result, the company has few prospects of developing a blockbuster drug for a mass market.

Is there a case to be made for a long-term investment in Biogen, given that its stock's recent performance has been decidedly poor?

Source Fool.com